GlassScriptPhysician profile
Flavia C Hoyte
NPI 1033361621
$70,146.25
in general payments reported to CMS, 2019-2025
10 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,913 · 2020: $1,056 · 2021: $10K · 2022: $9,937 · 2023: $25K · 2024: $4,581 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,425.25 |
| Food and Beverage | $531.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,376.32 | 2020-2025 | Tezspire, Airsupra |
| Genentech USA, INC. | $7,739.26 | 2023 | Xolair, Ocrevus |
| Glaxosmithkline, LLC. | $7,426.09 | 2019-2024 | Nucala |
| Teva Pharmaceuticals USA, INC. | $5,240.00 | 2023 | |
| Genentech, INC. | $3,730.34 | 2019 | |
| Genzyme Corporation | $3,534.00 | 2023-2025 | |
| Astrazeneca Uk Limited | $2,953.50 | 2025 | |
| Blueprint Medicines Corporation | $108.95 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $37.79 | 2024 | Dupixent |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavia Hoyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.